Patients with bone metastases from prostate cancer (PCa) and non-small-cell lung cancer (NSCLC) have been found to have elevated serum OPN levels, which are associated with poorer survival outcomes [40,52]. The gene discussed is SPP1; the disease is prostate cancer.